Clinical trials: Patients With Diabetes.
Type 2 Diabetes Mellitus (T2DM)
A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise
This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy and safety of BGM0504 in patients with type 2 diabetes (T2D) with poor glycemic control only through diet and…
- Trial name
- NCT06716203
- Testing
- Drug: 5 mg BGM0504 Administered SC, Drug: : 10 mg BGM0504 Administered SC
- Where
- China
- Volunteers
- 207 people
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Diabetes Mellitus, Type 2
Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes Patients
The objective of the current study is to investigate the efficacy, safety and tolerability of several doses of BI 1356 BS (0.5, 2.5 and 5 mg daily) compared to placebo over 12 weeks of treatment in patients with Type 2 diabetes…
- Trial name
- NCT00328172
- Testing
- BI 1356 dose 3 once daily, BI 1356 dose 2 once daily, BI 1356 dose 1 once daily
- Where
- 71 sites in United States, Australia and 4 more
- Volunteers
- 302 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
PF-06291874 Multiple Ascending Dose Study In Type 2 Diabetes Mellitus Patients
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of PF-06291874 in Type 2 Diabetes patients.
- Trial name
- NCT01856595
- Testing
- PF-06291874
- Where
- 3 sites in United States
- Volunteers
- 117 people
- Sponsor
- Pfizer
Type-2 Diabetes Mellitus
Early add-on Vildagliptin in Patients With Type 2 Diabetes Inadequately Controlled by Metformin
The purpose of this study was to observe change of HbA1c over time from baseline to month 12. The ultimate goal of this study was to provide a local reference value to the physicians \& patients in the future when they consider…
- Trial name
- NCT01766778
- Testing
- LAF237 (vildagliptin), Metformin
- Where
- 4 sites in Hong Kong
- Volunteers
- 117 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2
An Efficacy and Safety Study of Fixed-dose Rosiglitazone/Glimepiride to Treat Chinese Type 2 Diabetes Patients
The purpose of this study is to demonstrate that the rosiglitazone/glimepiride fixed-dose combination tablet will safely and effectively control glycemia as first-line oral therapy in drug naïve subjects with type 2 diabetes.
- Trial name
- NCT01453049
- Testing
- rosiglitazone/glimepiride fix dose combination, glimepiride
- Where
- 12 sites in China
- Volunteers
- 86 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2 DM
Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination
The efficacy and safety of a triple-pill combination therapy for advanced type 2 diabetes care. The study aims to assess the impact of 3 Oral Anti Diabetic (OAD) drugs on metabolic control, patient compliance, weight management…
- Trial name
- GLYCO-3P (NCT06862739)
- Testing
- Empagliflozin+Linagliptin+Metformin
- Where
- 2 sites in Pakistan
- Volunteers
- 800 people
- Sponsor
- Nabiqasim Industries (Pvt) Ltd
Macular Edema
A Study to Assess the Effectiveness of Aflibercept in Routine Clinical Practice in Patients With Diabetic Macular Oedema
Intravitreal aflibercept has been approved for the treatment of visual impairments due to diabetic macular oedema (DMO) in Europe and the US in August 2014 and July 2014 respectively.
- Trial name
- DRAKO (NCT02850263)
- Testing
- Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321), Anti-VEGF therapies including: Eylea Aflibercept, VEGF Trap-Eye, BAY86-5321) and Ophthalmologicals / Antineovascularisation agents (S01LA05)
- Where
- United Kingdom
- Volunteers
- 750 people
- Sponsor
- Bayer
Diabetes Mellitus, Type 2
To Assess the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes Mellitus Treated With Empagliflozin
To compare the risk of acute pancreatitis in patients with Type 2 diabetes mellitus (T2DM) newly initiating empagliflozin to that of patients newly initiating other oral non-incretin/non-Sodium glucose co-transporter-2 inhibitor…
- Trial name
- NCT05162014
- Testing
- empagliflozin, Oral non-incretin/non-sodium glucose co-transporter-2 inhibitors (SGLT2)-containing hypoglycaemic agents
- Where
- Germany
- Volunteers
- 494,679 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2, Health Knowledge, Attitudes, Practice
Improving Diabetic Patient Health Through Assistive-Reading Technology
Type 2 Diabetes Mellitus (T2DM) affects over 30 million Americans and requires patients to competently manage their conditions at home.
- Conditions
- Diabetes Mellitus, Type 2, Health Knowledge, Attitudes, Practice, Literacy
- Trial name
- NCT05337306
- Testing
- GogyUp Reader
- Where
- United States
- Volunteers
- 193 people, healthy volunteers welcome
- Sponsor
- GogyUp Inc
T2DM (Type 2 Diabetes Mellitus)
To Evaluate the Efficacy and Safety of Initial Combination Therapy With DWP16001 and DWC202518 Compared to DWP16001 Monotherapy and DWC202518 Monotherapy in Patients With Type 2 Diabetes Mellitus
This study aims to evaluate the efficacy and safety of initial combination therapy with DWP16001 and DWC202518 compared to DWP16001 monotherapy and DWC202518 monotherapy in patients with Type 2 Diabetes Mellitus
- Trial name
- NCT07619833
- Testing
- DWP16001, DWC202518
- Where
- South Korea
- Volunteers
- 510 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Type 2 Diabetes
A Safety PK/PD Study of SLV337 in Patients With Type 2 Diabetes
The purpose of this study is to assess safety, tolerability, pharmacokinetics and pharmacodynamics of SLV337 in patients with type 2 diabetes
- Trial name
- NCT00924534
- Testing
- SLV337
- Where
- 12 sites in Bulgaria, Poland and 1 more
- Volunteers
- 61 people
- Sponsor
- Abbott Products
Chronic Kidney Diseases, Diabetes
KidneYou - Innovative Digital Therapy
The aim of the study is to assess the improvement of health in patients affected by CKD when they are exposed to non-pharmacological treatment strategies as nutritional program (NP), physical activity program (PA) and mindfulness…
- Conditions
- Chronic Kidney Diseases, Diabetes, Arterial Hypertension, Chronic Glomerulonephritis
- Trial name
- NCT05286632
- Testing
- KidneYou APP
- Where
- Italy
- Volunteers
- 210 people
- Sponsor
- Advice Pharma Group srl
Diabetes Mellitus, Type 2, Obesity
Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus
This trial will evaluate use of BI 10773 as add-on to insulin regimen alone or with metformin in patients with typr 2 diabetes. Both lowering glucose and HbA1c and reducing the use of insulin in this population would provide…
- Trial name
- NCT01306214
- Testing
- BI 10773
- Where
- 103 sites in United States, Belgium and 12 more
- Volunteers
- 566 people
- Sponsor
- Boehringer Ingelheim
Diabetes, Diabetes Mellitus, Type 1
Comparison of Efficacy and Safety of Insulin Detemir and Insulin Glargine in Patients With Type 1 Diabetes
The trial is conducted in Europe and Africa. The aim of the trial is to compare the use of insulin detemir twice daily combined with mealtime insulin aspart against that of insulin glargine once daily combined with mealtime…
- Trial name
- NCT00312104
- Testing
- insulin detemir, insulin glargine, insulin aspart
- Where
- 46 sites in Austria, Germany and 1 more
- Volunteers
- 325 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Study of LY2881835 in Healthy People and People With Diabetes
This will be the first study in which LY2881835 is given to humans in order to evaluate the safety and any side effects of LY2881835 in humans as well as how long LY2881835 stays in the body and its effect on blood sugar levels.
- Trial name
- NCT01358981
- Testing
- LY2881835
- Where
- Singapore
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus, Chronic Kidney Disease Stage 3
Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control
Primary Objective: To demonstrate the superiority of Sotagliflozin 200 milligrams (mg) and Sotagliflozin 400 mg versus placebo on HbA1c reduction at 26 Weeks in participants with Type 2 diabetes who have inadequate glycemic…
- Trial name
- SOTA-CKD3 (NCT03242252)
- Testing
- Sotagliflozin
- Where
- 170 sites in United States, Argentina and 14 more
- Volunteers
- 787 people
- Sponsor
- Lexicon Pharmaceuticals
Hypoglycemia
Safety and Efficacy Study of Mini-Dose Glucagon (G-Pen Mini) in Patients With Type 1 Diabetes
The purpose of the study is to demonstrate that mini-doses of stable liquid glucagon (G-Pen Mini) produced by Xeris Pharmaceuticals are safe and effective as a treatment for mild to moderate hypoglycemia, a complication of…
- Trial name
- NCT02081014
- Testing
- G-Pen Mini™ (glucagon injection)
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Xeris Pharmaceuticals
Diabetes Mellitus, Type 2
A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus
The main purpose of this study is to evaluate the safety and efficacy of the study drug known as LY2963016 as compared to LANTUS® in adults with type 2 diabetes mellitus who are on 2 or more oral antihyperglycemic medications…
- Trial name
- ELEMENT 5 (NCT02302716)
- Testing
- LY2963016, LANTUS®, Oral Antihyperglycemic Medication
- Where
- 44 sites in United States, India and 5 more
- Volunteers
- 493 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes
A Trial to Compare BioChaperone Insulin Lispro Formulations With US Approved Humalog® and With EU Approved Humalog® in Patients With Type 1 Diabetes Mellitus
This is a single-centre, randomised, double-blind, 4-way crossover, 4-treatment, euglycaemic clamp study in subjects with Type 1 Diabetes Mellitus (T1DM).
- Trial name
- NCT04501107
- Testing
- Administration of BioChaperone insulin lispro reconstituted with Humalog® (IMP1), Administration of Ready-to-use BioChaperone insulin lispro (IMP2), Administration of US-approved Humalog® (IMP3)
- Where
- Germany
- Volunteers
- 32 people
- Sponsor
- Adocia
Type 2 Diabetes Mellitus
A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes
The purpose of this clinical research study is to determine whether dapagliflozin can improve (decrease) blood glucose values in patients with Type 2 diabetes and moderate renal impairment.This study will be conducted at…
- Trial name
- DERIVE (NCT02413398)
- Testing
- Dapagliflozin 10 mg
- Where
- 87 sites in United States, Bulgaria and 6 more
- Volunteers
- 321 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.